Altimmune (ALT) vs REGENXBIO (RGNX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
REGENXBIO (RGNX) has outperformed Altimmune (ALT) over the past year, losing 27.7% versus a loss of 32.3%. Over five years, ALT leads with a -77.9% price change compared with -78.9% for RGNX. REGENXBIO is the larger company by market cap ($538.7 million vs $501.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ALT | RGNX |
|---|---|---|
| Share price | $2.58 | $8.16 |
| Market cap | $501.86M | $538.67M |
| 1-day change | -3.00% | +7.44% |
| YTD return | -26.32% | -47.26% |
| 1-year return | -32.32% | -27.74% |
| 5-year return | -77.85% | -78.87% |
| EPS (TTM) | $-0.76 | $-3.78 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.44 | $16.19 |
| 52-week low | $2.55 | $5.46 |
| Distance from 52-week high | -59.94% | -49.60% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +563.18% | +188.97% |
| Average volume | 4.18M | 1.52M |
| Shares outstanding | 194.52M | 66.01M |
| Employees | 57 | 371 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Altimmune
ALT stock →Altimmune, Inc., a late clinical stage biopharmaceutical company, focuses on developing novel therapies for serious liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis, alcohol use disorder, and alcohol-associated liver disease.
Health Care · Biotechnology: Pharmaceutical Preparations · 57 employees
About REGENXBIO
RGNX stock →REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 371 employees
ALT vs RGNX FAQ
Which is bigger, Altimmune or REGENXBIO?
REGENXBIO (RGNX) is larger, with a market capitalization of $538.67M compared with $501.86M for Altimmune (ALT).
Which stock has performed better over the past year, ALT or RGNX?
RGNX returned -27.74% over the past 12 months, compared with -32.32% for ALT (price return, excluding dividends). Past performance does not predict future results.
Are Altimmune and REGENXBIO in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Altimmune and Biotechnology: Biological Products (No Diagnostic Substances) for REGENXBIO.